Stalicla

41st Annual J.P. Morgan HEALTHCARE CONFERENCE

The 41st Annual Healthcare Conference will take place on January 9-12, 2023 in San Francisco, CA. This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.   READ MORE

Welcome to the 2nd Rare CNS & Neurodevelopmental Drug Development Summit

Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients’ lives. …

Welcome to the 2nd Rare CNS & Neurodevelopmental Drug Development Summit Read More »

CONNECTING LIFE SCIENCE & HEALTHCARE EXECUTIVES WITH CAPITAL & PARTNERS

We hold events across the world including London, Switzerland, Boston and Copenhagen focused on connecting life science and healthcare companies with the investors and partners they need to grow.  Inv€$tival Showcase offers up 5 incredible stages for Startups, Series A, B and Public Biotech, Medtech, Healthtech and Women’s Health companies. They’ll deliver news and deal …

CONNECTING LIFE SCIENCE & HEALTHCARE EXECUTIVES WITH CAPITAL & PARTNERS Read More »

STALICLA completes successful phase 1b trials for the first precision medicine in autism spectrum disorder

Clinical data clear major test for the first precision neurodevelopmental disorders discovery platform, with a first application in Autism Spectrum Disorder (ASD) STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate …

STALICLA completes successful phase 1b trials for the first precision medicine in autism spectrum disorder Read More »

STALICLA at the first NDD Summit in 2021

We are very pleased to share the replay of STALICLA’s expert presentation at the first Neurodevelopmental Disorder Drug Development held in December. The first edition of the Neurodevelopmental Disorders Drug Development Summit was organized by Hanson Wade, a healthcare specialized initiative with the goal to accelerate progress within organizations and across industries. Their primary method …

STALICLA at the first NDD Summit in 2021 Read More »

Publication of our review on the Heterogeneity in Fragile X Syndrome

We are very pleased to announce the publication of our review on the Heterogeneity in Fragile X Syndrome (FXS) issued in Frontiers in Psychiatry. This article was written within the scope of the recent collaboration between STALICLA DDS in Barcelona and DDU in Geneva.It highlights the need for precision medicine-based treatments in neurodevelopmental disorders, with …

Publication of our review on the Heterogeneity in Fragile X Syndrome Read More »

STALICLA featured in swiss magazine PME

Dix jeunes pousses suisses intègrent le premier programme Venture Leaders dédié au secteur des biotechnologies et iront cet automne à la rencontre d’investisseurs internationaux et des leaders du secteur. Parmi ces start-up sélectionnées, notamment, par Venturelab et Swissnex, trois romandes: Alithea Genomics, Gnubiotics Sciences et Stalicla. READ MORE

STALICLA at MedInvest – Neurological Diseases & Mental Health Disorders Conference

Geneva, Switzerland, September 8, 2021 — STALICLA, a Swiss clinical-stage biotech company advancing precision medicine to patients with Autism Spectrum Disorders and other Neurodevelopmental Disorders, announced today that its CEO and Founder, Lynn Durham, will present at the THE NEUROLOGICAL DISEASES & MENTAL HEALTH DISORDERS CONFERENCE, on September 9, 2021. Ms Durham’s presentation will take …

STALICLA at MedInvest – Neurological Diseases & Mental Health Disorders Conference Read More »

STALICLA at Swiss Biotech Day 2021

STALICLA, a Swiss clinical-stage biotech company advancing precision medicine to patients with Autism Spectrum Disorders and other Neurodevelopmental Disorders, announced today that its CEO and Founder, Lynn Durham, will present at the Swiss Biotech Day, on September 7, 2021 at the Congress Center in Basel – Switzerland. STALICLA’s presentation will take place within the Emerging …

STALICLA at Swiss Biotech Day 2021 Read More »